Introduction
DNA vaccination is a promising new strategy for tumor immunotherapy. Direct intramuscular (i.m.) injection of naked plasmid DNA can elicit a full spectrum of immune responses including antibodies, CD8
+ cytotoxic T lymphocytes (CTLs), and CD4
+ T-helper type 1 (Th1) or type 2 (Th2) responses to the antigen encoded by the DNA vaccine. In animal models, the immune responses elicited often provide protection against a challenge with malignant tumor cells (reviewed in Ref. 1) . Thus, when animals are inoculated with DNA vaccines encoding xenogeneic tumor-associated antigens (TAAs) such as human carcinoembryonic antigen (CEA), [2] [3] [4] [5] ␤-galactosidase (␤-gal), 6 or SV40 large tumor antigen, 7 many are protected from a subsequent challenge with syngeneic tumor cells expressing the relevant TAA. Furthermore, DNA vaccines can induce tumor immunity in cases where the antigen encoded is a self TAA, such as neu/erbB2, 8, 9 or mouse gp75/tyrosine related protein-1. 10 Notably, DNA vaccination offers the possibility of enhancing or modulating immune responses by codelivery of plasmid vectors encoding a cytokine (eg IFN␥, IL-12, GM-CSF) or immune costimulatory molecule (eg B7 or CD40 ligand) (reviewed in Ref. 11) . perforin, could fully resist a tumor challenge. IL-12 stimulated CTL activity, which was strictly CD3/CD8/perforindependent. FasL-KO mice had normal CTL activity and tumor resistance, indicating that only the perforin lytic pathway was involved. CD4-KO and IFN␥-KO mice still generated CTLs. CEA-stimulated IFN␥ production occurred in both CD4-or CD8-KO mice and in both cases was augmented by IL-12. In IFN␥-KO mice, IL-12 still enhanced anti-CEA antibody production but only moderately restored impaired DTH and tumor resistance. We conclude that the immune requirements for tumor rejection are stringent, involving multiple mechanisms which are all enhanced by IL-12. Gene Therapy (2000) 7, 1527-1535.
We have used human CEA as an antigen in mice, to study strategies of DNA vaccination. 5 There are no highly homologous genes in the mouse, and our study was intended to study immune responses to a xenoantigen. However, a family of murine CEA-related genes has 50-60% homology with human CEA. 4 We found that coinjection of a CEA-encoding plasmid with either an IL-12 or an IFN␥ plasmid strongly enhanced tumor immunity against CEA-positive P815 cells in DBA/2 mice. Both cytokine vectors enhanced the Th1 response, anti-tumor CTL activity and IgG anti-CEA antibody levels, but IL-12 had the strongest effect. In contrast, coinjection of an IL-4 vector depressed anti-CEA Th1 and CTL responses and reduced tumor immunity. Furthermore, injection of the IL-12 vector alone (no CEA) or in a different muscle than the CEA vector had no immunotherapeutic effect, suggesting that IL-12 acted through a local adjuvant effect. It was not clear, however, which immune effector mechanisms were responsible for tumor rejection.
In this study, to analyze immune requirements for tumor rejection, after vaccination we transplanted C57BL/6-derived Lewis lung carcinoma (LLC) cells stably transfected with CEA (CEA/LLC cells) into mice. C57BL/6-background gene knockout (KO) strains, deficient in either CD3, CD4, CD8, IFN␥, perforin (pore forming protein (Pfp)) or Fas ligand (FasL), were immunized against CEA. In accordance with our previous studies, i.m. injection of a CEA plasmid elicited both humoral and cellular anti-CEA immune responses, and partial inhibition of the growth of transplanted CEA/LLC cells. However, tumors still appeared in 100% of mice. Coinjection of a p35/p40-bicistronic IL-12 plasmid promoted greater resistance to a tumor challenge in all strains, except CD3-KO mice which had no observable immunity. With IL-12, 80% of wild-type (WT) C57BL/6 mice remained free of tumor. CD4 and CD8 expression were both required and equally important for generation of an optimal response, and essentially all cytolytic activity against CEA/LLC cells could be attributed to the perforin pathway. Interestingly, though IFN␥-KO mice had low delayed-type hypersensitivity (DTH) reactions to tumor cells and were impaired in their ability to resist tumor growth, their responses were partially restored by IL-12. Thus, DNA vaccination appears to induce a number of protective immune effector mechanisms, which are all augmented by IL-12.
Results
IgG anti-CEA serum levels We previously found that four or five DNA injections were required to generate CTLs and optimal antibody titers consistently. 5 For this reason, all experiments in this study were performed with five DNA injections at weekly intervals. One week after the last DNA injection, serum samples were collected for quantitation of IgG anti-CEA antibody.
As shown in Table 1 , serum IgG anti-CEA antibodies were undetectable in blank vector treated mice, and significant production of anti-CEA antibody was elicited by i.m. injection of pCMV-CEA in C57BL/6 WT, CD8-KO, FasL-KO, perforin-KO (Pfp-KO), IFN␥-KO, and neo r Tg mice. Coinjection of VR-IL12 with pCMV-CEA increased the production of IgG anti-CEA antibody equally in all groups, except CD3-KO and CD4-KO mice that could not be induced to produce antibody with or without IL-12. This suggests that without help from functional CD4 + T cells, B cells cannot produce antigen-specific IgG anti- body. Lack of CD8, FasL, or perforin does not seem to affect antigen-specific IgG production in these mice.
Detection of CTL response against CEA-expressing tumor cells in vitro Seven days after the last of five DNA injections, spleen cells were recovered and incubated with purified human CEA for 5 days in medium supplemented with IL-2. In this assay, CEA is presented by APCs by processing of exogenous antigen through the class I MHC pathway (cross-presentation), resulting in cross-priming of CTLs.
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Stimulation with CEA/LLC cells, performed as we have described previously, 5 generated lower levels of cytotoxicity than stimulation with soluble CEA (data not shown). After 5 days in culture, the cells were tested for CTL activity. In addition to WT and KO stains, neo r Tg mice were included as a control in our experiments since these mice are naturally tolerant to neomycin phosphotransferase (NPT), and this antigen is expressed by the CEA/LLC stable transfectant cells.
As shown in Figure 1 (a and b), spleen cells from either WT, CD4-KO, FasL-KO, IFN␥-KO or neo r Tg mice injected with a mixture of pCMV-CEA and blank VR vector generated a CTL response against CEA/LLC cells. Coinjection of VR-IL12 with pCMV-CEA significantly increased CTL activity, except in CD3-KO, CD8-KO and Pfp-KO mice that generated minimal cytotoxicity with or without IL-12. Spleen cells from either CD4-KO or IFN␥-KO had mildly depressed CTL activity compared with WT mice, which could be enhanced by IL-12. Neo r Tg mice had responses similar to WT mice, suggesting that CEA, but not NPT, is the target antigen. In any case, the mice were not immunized against NPT, and we previously determined in a DNA vaccination study that this protein is poorly antigenic. 5 In all groups, no CTL activity was detected against parental LLC target cells (not shown).
The maximum cytotoxicity recorded in these experiments is relatively low but reproducibly significant (reported at effector:target ratios of 50:1 and 100:1 in Figure 1a and b, respectively). The background cytotoxicity against CEA-negative LLC cells was always very low (Ͻ2%). The cytotoxicity of T cells from blank vectortreated mice against CEA-positive cells was also low (Ͻ2.5%). Moreover, the results were reproducible in three consecutive experiments, and cytotoxicity was detectable in all mouse strains except those lacking either CD3, CD8, or Pfp. In all responding strains, cytotoxicity was reproducibly enhanced by IL-12, as confirmed by statistical significance tests. The low level of cytotoxicity achieved may be related to the fact that LLC cells express only low levels of MHC class I antigens, as we confirmed by flow cytometry analysis (data not shown).
Secretion of IL-4 and IFN␥ by spleen cells in vitro
Spleen cells from plasmid-inoculated mice were recovered 1 week after the last of five DNA injections, and stimulated in culture with purified CEA protein. Analysis of supernatants by ELISA revealed that spleen cells from either WT, FasL-KO, Pfp-KO, or neo r Tg mice injected with a mixture of pCMV-CEA and blank VR vector produced substantially more IFN␥, and slightly more IL-4, when compared with control mice (pCMV + VR) (Figure 2 ). Spleen cells of mice coinjected with pCMV- CEA and VR-IL12 had a further increase in the levels of IFN␥ and produced very low levels of IL-4.
Spleen cells from CD3-KO mice produced only minimal levels of either IL-4 or IFN␥, regardless of plasmid. Deletion of CD8 did not reduce IFN␥ production, or its responsiveness to IL-12. However, the spleen cells of CD4-KO mice generated moderately lower levels of IFN␥, that could be enhanced by IL-12. Nevertheless, CD4-KO mice still produced considerable amounts of IFN␥. CEA but not a control antigen (ovalbumin) was required to induce cytokine secretion, ie the response was antigen specific. This is consistent with a T cell-mediated response, along with the lack of response in CD3-KO Gene Therapy mice, since NK or other cells are not expected to respond specifically to antigen in this way. Spleen cells from IFN␥-KO mice injected with pCMV-CEA + VR showed increased IL-4 production compared with control mice (pCMV + VR), and this increase was much less when VR-IL12 was coadministered. As expected, spleen cells from IFN␥-KO mice did not produce any detectable IFN␥.
Induction of DTH reaction
DTH is a Th1-dependent response, where IFN␥ is thought to play a key role. However, the significance of DTH in tumor rejection is not always clear. To examine whether i.m. injection of pCMV-CEA (with or without VR-IL-12) can induce in vivo Th1-type responses, a footpad assay of the DTH response to CEA/LCC was used. One week after the last of five DNA injections, the mice received injections of irradiated LLC cells into the right hind paw, and irradiated CEA/LLC cells into the left hind paw. DTH reactions (footpad swelling) were measured 48 h later.
As shown in Figure 3 , CD3-KO and CD4-KO mice had virtually no DTH reaction (with or without IL-12). All other strains had comparable responses, except for an impaired reaction in IFN␥-KO mice. VR-IL-12 coinjection augmented DTH reactions in all strains, except the CD3-and CD4-KO strains. The CD3/CD4/IFN␥ dependence of the response is consistent with previous studies. However, our results show that DTH occurs, and is IL-12 responsive, in mice completely lacking IFN␥. There was no significant difference in thickness between the right and left hind footpads before the inoculation of irradiated cells (not shown). Protection by DNA vaccination against a tumor cell challenge One week after the last of five DNA injections, mice were transplanted with CEA/LLC cells or parental LLC cells. Tumor volumes were measured over a period of 28 days. WT C57BL/6 mice injected with plasmids and challenged with parental LLC cells had a high tumor growth rate, and were not protected by pCMV-CEA (with or without VR-IL-12) (Figure 4a ). Mice injected with blank vectors (pCMV + VR), or pCMV + VR-IL12, but challenged with CEA/LLC cells suffered a similarly high tumor growth rate (Figure 4b) . Thus, the IL-12 vector is not protective without CEA immunization, as we have previously reported. 5 However, injection of pCMV-CEA + VR into WT, FasL-KO, and neo r Tg mice considerably inhibited the growth CEA/LLC tumors (Figure 4b-d) , but tumors still appeared in 100% mice by day 28 (not shown). Coinjection of VR-IL-12 with pCMV-CEA significantly enhanced protection (Figure 4b-d) . Most experiments were terminated at day 28, but the WT mice were observed longer. At day 60, 80% of WT mice inoculated with both the CEA and IL-12 plasmids survived tumor free, compared with none in WT mice receiving the CEA but not the IL-12 plasmid (not shown; P Ͻ 0.02). There is no evidence that expression of NPT in neo r Tg mice inhibits or alters tumor immunity (Figure 4c ).
CD3-KO mice did not respond to immunization with pCMV-CEA, and this was not ameliorated by VR-IL-12 (Figure 4e ), suggesting that the antitumor immunity is entirely T cell-dependent, and there is no IL-12 effect independent of pCMV-CEA immunization.
All other strains (Pfp-KO, CD4-KO, CD8-KO and IFN␥-KO) responded to vaccination but had considerably impaired tumor resistance compared with WT mice (Figure 4f-i) . In all these cases, VR-IL-12 moderately but significantly improved resistance to tumor growth, but could not restore the response to normal intensity. This suggests that optimal tumor rejection requires a collaboration of effector mechanisms involving CD4 + cells, IFN␥ secretion, CD8
+ cells and perforin-mediated cytolysis. However, inasmuch as the FasL-KO mice have a normal antitumor response (Figure 4d) , the Fas-dependent cytolytic pathway does not appear to be involved.
Discussion
Codelivery of antigen and cytokine plasmid vectors is an effective strategy for enhancement or modulation of immune responses. 1, 11 We previously reported that i.m. injections of a plasmid encoding CEA elicited both humoral and cellular immune responses in mice, but only partial inhibition of the growth of transplanted syngeneic CEA-positive murine mastocytoma P815 tumor cells (CEA/P815). We showed that immunity elicited by i.m. DNA vaccination against CEA can be biased to a protective type (high Th1 and CTL activity) by coinjection of either IL-12 or IFN␥ plasmids, or nonprotective type (high Th2 and low CTL activity) by coinjection of an IL-4 plasmid. IL-12 appeared to act locally, but not systemically, through an adjuvant effect. Moreover, the adjuvant effects of the IL-12 vector were superior to those of the IFN␥ vector, but in either case the mechanisms of tumor rejection were not determined.
In this study, we analyzed the immune requirements for tumor rejection by injecting the CEA/LLC transplantable cell line into immune-gene KO mice of C57BL/6 genetic background. The use of gene KO mice provides a straightforward method of identifying genes that are essential for effective protective immunity. This model was chosen because LLC is a well-studied highly malignant carcinoma line derived from a C57BL/6 mouse, and an appropriate panel of gene-KO mice was available. C57BL/6-background mice, with or without gene deletions, were immunized by i.m. injections of a mixture of a CEA vector (pCMV-CEA) and either a blank vector (VR) or an IL-12 vector (VR-IL-12). The blank vector was injected to control for the amount of bacterial DNA administered.
CEA-plasmid-immunized CD3-KO and CD4-KO mice both failed to produce detectable anti-CEA antibody, corresponding to the known CD3/CD4 + T cell requirement for effective anti-protein antigen antibody production. Other KO genes were not essential since all other strains, ie CD8-KO, pfp-KO, FasL-KO and IFN␥-KO, responded similarly well to vaccination. I.m. injection of the CEA vector plus VR induced significant production of IgG anti-CEA antibody, and coinjection of VR-IL-12, instead of the blank vector, enhanced anti-CEA IgG levels.
IL-12 has multiple effects that may promote antibody production. This could be indirect through enhanced Th1-cell activity and IFN␥ secretion, which results predominantly in the production of IgG2a. 5 However, since we observed that IL-12 was able to enhance IgG production in IFN␥-KO mice, other mechanisms must also be involved. B cells express IL-12 receptors, 13 and can respond to this cytokine. Notably, IL-12 secreted by CD40-activated dendritic cells (DCs) promotes differentiation of naive B cells.
14 In a previous study, 5 we established that VR-IL12 preferably induces IgG2a secretion, 
/LLC cells or parental LLC cells were injected s.c. into the left flank of each mouse. The volume of the tumors was determined every two days. -᭺-, injection with blank vectors (pCMV + VR); -᭹-, injection with pCMV-CEA + VR; -̄-, injection with pCMV-CEA + VR-IL12; --, injection with pCMV + VR-IL12. (a) WT mice injected with plasmid vectors and challenged with parental LLC cells. The other groups of mice (from b to i) were injected with plasmid vectors and challenged with CEA/LLC cells. b, WT mice; c, neo r TG mice; d, FasL-KO mice; e, CD3-KO mice; f, Pfp-KO mice; g, CD4-KO mice; h, CD8-KO mice; i, IFN␥-KO mice. Each value represents the mean ± s.e.m. (n = 5 per group). Similar results were obtained in one repeat experiment. Statistical analysis of CEA/LLC tumor volumes on day 28 post tumor transplantation was performed, and significant values are as follows: P Ͻ 0.001 in the comparison of (pCMV + VR) versus (pCMV-CEA + VR) within each genotypic group of mice except CD3-KO mice. P Ͻ 0.01 in the comparison of (pCMV-CEA + VR) versus (pCMV-CEA + VR-IL12) within WT, FasL-KO, and neo r TG groups. P Ͻ 0.01 in the comparison of (pCMV-CEA + VR) for groups of either WT, FasL-KO, or neo r TG mice versus groups of either CD4-KO, CD8-KO, Pfp-KO, or IFN␥-KO mice; P Ͻ 0.001 for CD3-KO mice receiving pCMV-CEA (with or without VR-IL-12) and a CEA/LLC challenge versus all the other groups receiving pCMV-CEA and a CEA/LLC challenge. Injection of pCMV + VR-IL12 (WT mice) had no significant effect compared with injection of blank vectors.
consistent with a Th1-mediated response. Unfortunately, since C57BL/6 mice do not express this IgG isotype, 15 we were not able to confirm whether this type of Th1 bias was still observed in IFN␥-KO mice.
The effector mechanisms involved in an antitumor response may vary, depending on the nature of the tumor Here, we found that injection of pCMV-CEA + VR generated similar levels of anti-CEA/LLC CTL activity in either WT, FasL-KO, or neo r Tg mice. Coinjection of the CEA and IL-12 vectors enhanced CTL-mediated cytolysis. Interestingly, this CTL activity was relatively low and less than we previously recorded against CEA/P815 target cells in CEA-immunized DBA/2 mice. 5 A likely reason is that CEA/LLC cells, unlike CEA/P815 cells, express only low levels of MHC class I (H-2 b ) molecules (our unpublished observations), which is not an unusual finding in highly malignant tumor cells. CEA also appears to be a relatively poor antigen for CTL assays, and our results are comparable to those reported by other authors after vaccination against CEA with a viral vector. 18 However, in our study, CEA-specific cytotoxicity was reproducibly detected from the cells of WT mice and all other strains, provided they expressed CD3, CD8 and Pfp. Furthermore, cytotoxicity was enhanced by IL-12 in all the responsive strains in a consistent and statistically significant fashion. Thus, it is apparent that VR-IL12 is enhancing CTL activity, as we have previously shown against CEA/P815 target cells.
No significant CTL-mediated cytolysis was detected from lymphocytes of either CD3-KO, CD8-KO, or Pfp-KO mice injected with the same plasmids as other groups. Thus, our results indicate that the in vitro cytolytic activity was CD3/CD8/perforin-dependent, which corresponds to the phenotype of classical CTLs, and FasL does not appear to be involved. Our results in tumor challenge experiments (see below) also suggest a protective role for T cells of this phenotype.
In a DNA vaccination study against a CEA-expressing colon carcinoma cell line Conry et al 3 identified CD4 + T cells as key effector cells in tumor rejection, using a Winn assay. However, unlike us, these authors did not identify a CD8
+ CTL contribution, either in vitro or in vivo. The reason for this discrepancy is unclear, but may be related to the properties of the tumor cells used in their study, or a different protocol of DNA immunization. Moreover, these authors did not co-inject an IL-12 vector to enhance CTL activity. They have shown, however, that co-delivery of B7-1 with CEA with a dual expression plasmid produces superior antitumor immunity than injection of the CEA plasmid alone, or injection of the two genes on separate plasmids.
All cytotoxic activity measured in a standard CTL assay can be attributed to perforin and FasL. 19 In our experiments, FasL-KO have normal CTL responses, but this is perhaps not surprising, since we find that CEA/LLC cells have no detectable or at least very low levels of membrane Fas protein (our unpublished observation). Thus, we cannot exclude the possibility that DNA vaccination generated killer cells that could have operated through that pathway against Fas + cells. In our assays, cytolysis was unlikely to be mediated by NK cells, since lysis was only observed with CEA/LLC target cells, but not parental LLC CEA-negative cells. NK cells would be unable to show this type of antigen specificity. Furthermore, there was no increase in NK-mediated lysis in immunized versus control mice when NK-sensitive YAC-1 target cells were used as targets in the assay (not shown).
The CTL responses detected from either CD4-KO or IFN␥-KO mice were only mildly lower than those from WT, FasL-KO, or neo r Tg mice. Interestingly, neither CD4 + cells nor IFN␥ is essential to induce CTL activity, and IL-12-mediated enhancement is still apparent. This reveals IFN␥-independent activities of IL-12 on CTLs.
Furthermore, our results are consistent with previous studies showing that CTLs can be induced in the absence of CD4 + T cell-mediated help. 20, 21 When the spleen cells from CEA plasmid-inoculated WT mice were stimulated in culture with purified CEA protein they produced substantially more IFN␥, and slightly more IL-4, compared with empty vector-treated control mice. Administration of VR-IL12 further increased the levels of IFN␥ and suppressed IL-4. Spleen cells from CD3-KO mice produced only minimal levels of either IL-4 or IFN␥, regardless of plasmid injections, suggesting that these cytokines were secreted almost entirely by T cells. Deletion of CD8 did not reduce IFN␥ production, or its responsiveness to IL-12. However, the spleen cells of CD4-KO mice generated moderately lower levels of IFN␥, that could be enhanced by IL-12. Nevertheless, CD4-KO mice still produced considerable amounts of IFN␥. Inasmuch as IFN␥ production was limited to wells containing CEA but not a control antigen (ovalbumin), ie the response was antigen specific, it appears that T cells (CD4 + or CD8 + ) are being activated in these assays, and that both T cell types can secrete IFN␥. NK cells (that can also produce IFN␥) do not respond in this antigen-specific manner. They can respond directly to IL-12, but this was not evident in CD3-KO mice. Nonetheless, we cannot exclude that NK cells were stimulated to produce IFN␥ indirectly by T cell-derived cytokines.
Interestingly, spleen cells from IFN␥-KO mice injected with pCMV-CEA + VR showed increased IL-4 production compared with control mice (pCMV + VR), and this increase was much less when VR-IL12 was coadministered. Whether IL-4 altered tumor immunity is unknown, but in a different tumor model we found IL-4 to be detrimental. 5 As we anticipated, DTH reactions to CEA/LLC were entirely CD3/CD4-dependent, and CD8/perforin/FasLindependent. IFN␥-KO mice still mounted DTH reactions, but considerably weaker than those of WT mice. Presumably, this results from a lack of Th1-derived IFN␥-mediated macrophage activation. IL-12 probably augments DTH largely by inducing IFN␥ secretion. 22 We found that coinjection of the IL-12 vector only partially restored the DTH. However, inasmuch as IL-12 has stimulatory activity, it appears that IL-12 enhances DTH through both IFN␥-dependent and -independent pathways.
Clearly, the most relevant measure of successful immunization is resistance to a tumor challenge. DNA immunization against CEA in WT C57BL/6 mice strongly protected against the growth of CEA/LLC cells, but not parental LLC cells. CD3-KO mice did not respond to CEA vaccination, with or without VR-IL-12, indicating that protective immunity was entirely T cell-dependent. When compared with WT mice, there was no reduction in protective immunity in FasL-KO mice. Resistance to CEA/LLC growth clearly results from a CEA-specific immune response. The CEA/LLC cells also produce NPT, a potential target antigen. However, we found that tumor resistance was normal in CEA-vaccinated neo r Tg mice, which are naturally immunologically tolerant to NPT due to expression starting in fetal life. Thus, there is no indication that immunity to NPT is a contributory factor in our experiments.
Though injection of pCMV-CEA into WT, FasL-KO, and neo r Tg mice considerably inhibited the growth CEA/LLC cells, tumors still appeared in 100% of mice. Coinjection of VR-IL-12 with pCMV-CEA in WT mice completely blocked tumor growth in many mice, such that 80% were tumor-free for over 2 months after transplantation. Immunized mice deficient in either CD4, CD8, perforin or IFN␥ could all generate some protective tumor immunity, but it was considerably impaired compared with WT mice. The antitumor response of these four groups were similar in intensity, and in all cases immunity could be ameliorated by VR-IL-12. This IL-12 effect was modest, but statistically significant. Taken together, our data suggest that optimal tumor rejection requires a collaboration of effector mechanisms involving CD4 + cells, IFN␥ secretion, CD8 + cells and perforinmediated cytolysis. Most likely, CD4
+ cells act through an IFN␥-dependent DTH-like mechanism, while CD8
+ cells directly kill tumor cells.
VR-IL-12 has a strong adjuvant effect. In accordance with a previous study, 5 we found that in C57BL/6 mice the IL-12 vector must be injected at the same muscle site as the CEA vector to exert this adjuvant action (data not shown). Although we have not addressed this question, the requirement for colocalization of the vectors suggests that either the APC presenting CEA needs to be transfected with the IL-12 vector, or IL-12 must be secreted in close proximity to the APC for effective T cell activation. We find no evidence that the levels of circulating IL-12 generated by our method contribute to the enhancement of the anti-CEA immune response, or directly inhibit the growth of either P815 cells 5 or LLC cells (this study). One important aspect of DNA vaccination is that plasmid DNA itself has immunostimulatory sequences (ISS), which contain unmethylated CpG dinucleotides, [23] [24] [25] which directly activate APCs. ISS have been identified in the bacterial ampicillin resistance gene (a component of pCMV-CEA), the CMV promoter sequence, and are likely to be present in any plasmid backbone DNA. Thus, ISS sequences undoubtedly contribute to immunity in our experiments. However, immunization with pCMV-CEA plus blank VR could not protect mice from transplanted tumors. Evidently, ISS sequences cannot mimic or replace the strong adjuvant of IL-12 and are insufficient to generate fully protective tumor immunity in our models.
In conclusion, we found that protective immunity was equally dependent on CD4 and CD8 expression, IFN␥ significantly contributed to the response, and IL-12 exerted multiple protective effects that were both IFN␥ dependent and independent. Immune responses to xenoantigens, such as CEA in mice, may differ in many ways from responses to self TAAs. However, in clinical or preclinical studies, gene therapy approaches have been used to introduce genes encoding alloantigens or xenoantigens directly into tumors. 26, 27 Thus, intra-tumor xenoantigen gene transfer could be combined with prior or concurrent i.m. DNA vaccination against this antigen to promote eradication of tumors. In terms of immune mechanisms, this is similar to our model and suggests potential clinical applications.
Materials and methods

Plasmid construction
The vectors used in this study have been previously described. 5 Briefly, cDNA containing the complete coding 28 After removal of the original luciferase gene, we inserted the p35 and p40 cDNA sequences of murine IL-12, a synthetic intron (IVS) and an internal ribosomal entry site (IRES) in this order: p35/IVS/IRES/p40/terminator. VR-IL-12 has CMV IE-EP sequences, CMV intron A, and a minimal rabbit beta-globin transcriptional terminator. An empty VR1255-derived vector (luciferase gene deleted), designated VR, was used as a control in several experiments. Transfection of COS-7 cells with VR-IL-12 revealed secretion of bioactive IL-12p70. I.m. injection of this vector as performed in the current study elevates serum total IL-12 by 100-200 pg/ml and IL-12p70 by 2-4 pg/ml. 5 ELISA assays IFN␥ and IL-4 levels in culture supernatants were measured by ELISA kits (R&D Systems, Minneapolis, MN, USA; detection limit, less than 2 pg/ml, both assays), according to the manufacturer's instructions.
Plasmid DNA preparation Plasmid DNA was prepared as previously described by the alkaline lysis method using Qiagen Mega Prep kits (Qiagen, Santa Clarina, CA, USA), 5 according to the manufacturer's instructions. DNA prepared for i.m. injections was dissolved in sterile 0.85% NaCl and stored at −80°C. Spectrophotometric analysis revealed 260/280 nm ratios ranging from 1.80 to 2.0. Purity of DNA preparations and conformation was confirmed by electrophoresis with 1% agarose gel. The samples contained less than 5 ng of lipopolysaccharide per microgram of DNA as determined with the Limulus amebocyte lysate analysis kit (BioWhittaker, Walkersville, MD, USA), with little variation between samples.
Establishment of the CEA transfected mouse tumor cells The murine Lewis lung carcinoma (LLC) cell line of C57BL/6 (H-2 b ) origin was used for establishment of a CEA-expressing stable transfectant cell line. To facilitate efficient production of stable transfectant lines, CEA cDNA from pCI-CEA vector was transferred into the bicistronic expression vector pIRES1neo (Clontech, Bio/Can Scientific, Mississauga, Ontario, Canada). LLC cells were transfected with the pIRES-CEA vector using lipofectamine (Gibco BRL, Grand Island, NY, USA) according to the manufacturer's instructions. Transfected cells were then selected in geneticin-containing medium, individual G418-resistant colonies picked, and CEA-positive transfectants identified by flow cytometry after staining with anti-CEA mAb (B18) and goat anti-mouse-FITC conjugate. The stable transfectant clone of LLC cells expressing CEA used in this study was designated CEA/LLC. These cells were used as target in cytotoxicity assays and for transplantation in tumor challenge experiments. Expression of CEA on at least two-thirds of cells was reconfirmed before use in each experiment. An optimal DNA vaccination protocol was established in a previous study. 5 Unless indicated otherwise, 8-to 10-week-old mice were anesthetized and injected i.m. in the rectus femoris muscles of both legs with 50 g of pCMV-CEA vector, mixed with 100 g of a blank vector VR, or 100 g of VR-IL12 in a total volume of 75 l of saline, using a disposable sterile plastic insulin syringe and 29G1/2 needle (VWR Canlab, Missisauga, Ontario, Canada). Mice injected with 50 g of blank vector pCMV mixed with 100 g of the blank vector VR were used as control groups. In all experiments, five identical weekly injections were administered.
Mice and immunization protocol
Quantitation of CEA antibody
This was performed as previously described. 5 Briefly, serum samples were assayed for the presence of anti-CEA antibodies by a cellular enzyme-linked immunoabsorbent assay (CELISA). The CEA-producing human adenocarcinoma cell line LS180 (kindly provided by Dr Abraham Fuks, McGill University, Montreal, Canada) was used as a CEA antigen source in the assay. Concentrations of total IgG anti-CEA Ab were calculated from the standard curve generated by IgG anti-CEA mAb and results are reported as units (U), where 1 U of anti-CEA antibody = 1 g of anti-CEA mAb. Cytotoxicity assay A previously described technique was slightly modified. 5 Spleen cells (4 × 10 6 per well) were first cultured in medium consisting of RPMI 1640 (Gibco RBL), containing 10% FBS, purified human CEA (100 g/ml; kindly provided by Dr Abraham Fuks, McGill University), or ovalbumin (100 g/ml; Sigma Chemical, St Louis, MO, USA) as a negative control antigen, and supplemented with 20 U/ml human rIL-2 (MEDICORP, Montreal, Quebec) in 24-well plates at 37°C for 5 days, for in vitro stimulation of the responder spleen cells.
To perform the chromium-release assay, target CEA/LLC cells and parental LLC cells (2 × 10 6 cells) were labeled with 200 Ci of Na 2 51 CrO 4 (Amersham, Oakville, Ontario, Canada). The target cells and the in vitro-stimulated responder cells were then combined at various effector to target ratios in 96-well, U-bottom plates (Fisher Scientific, Whitby, Ontario, Canada) in a volume of 200 l per well. After a 6-h incubation at 37°C, 100 l of supernatant was harvested from each well and radioactivity was quantitated in a gamma counter. The percent specific lysis was determined using the following equation: percent lysis = ((experimental release − spontaneous release)/(maximum release − spontaneous release)) × 100.
Cytokine release assay For measuring cytokine release by lymphocytes, spleen cells from the experimental or control animals were cultured with purified human CEA or ovalbumin in 24-well plates, in the same conditions as described above for the cytotoxicity assay, except that the culture was maintained for 3-4 days. Then, cell-free supernatants were harvested and stored at −80°C. The supernatant samples were assayed for the presence of IFN␥ and IL-4 by ELISA. 
Induction and measurement of DTH reaction
Statistical analysis
The statistical significance of differences among various groups of mice for all data except survival was determined by analysis of variance, with the SYSTAT statistical software (version 8.0, SPSS, Chicago, IL, USA). The significance of survival data was determined with Fisher's exact test.
